Search
AdimrSC-2f
go.drugbank.com/drugs/DB16436InvestigationalA phase I study (NCT04522089) will investigate the safety and immunogenicity of the vaccine[L30553, L30548]. … The AdimrSC-2f (SARS-CoV-2) vaccine is developed through Adimmune Corporation, the only influenza vaccine manufacturer with both EU GMP and US FDA certification in Asia[L30553].
Mepolizumab
go.drugbank.com/drugs/DB06612ApprovedInvestigationalThe pathogenesis of eosinophilia is complex, but IL-5 is recognized as a key cytokine involved in the differentiation, recruitment, activation, and prolonged survival of eosinophils in peripheral tissue … Mepolizumab was first approved by the FDA on November 4, 2015, as an add-on therapy for severe asthma and marketed under the brand name Nucala by GlaxoSmithKline.
Mogamulizumab
go.drugbank.com/drugs/DB12498ApprovedInvestigationalMogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of … Food and Drug Administration (FDA) approved mogamulizumab injection (also known as _Poteligeo_) for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF
Ceritinib
go.drugbank.com/drugs/DB09063ApprovedInvestigationalThe FDA approved ceritinib in April 2014 due to a surprisingly high response rate (56%) towards crizotinib-resistant tumours and has designated it with orphan drug status. … About 4% of patients with NSCLC have a chromosomal rearrangement that generates a fusion gene between EML4 (echinoderm microtubule-associated protein-like 4) and ALK (anaplastic lymphoma kinase), which
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexGeraniol
go.drugbank.com/drugs/DB14183ApprovedSensitivity to geraniol may be identified with a clinical patch test. … Geraniol has demonstrated a wide spectrum of pharmacological activities including antimicrobial, anti-inflammatory, antioxidant, anti-cancer, and neuroprotective to name a few [A34260,A34261,A34262].
Sonrotoclax
go.drugbank.com/drugs/DB18753ApprovedInvestigational[L56193,A275521] Sonrotoclax was rationally designed as a BH3 mimetic with a shallow and broad interaction with the P2 pocket of BCL-2, achieved through a novel 7-azaspiro[3.5]nonane linker; this binding … lines of systemic therapy, including a BTK inhibitor.
Florquinitau (18F)
go.drugbank.com/drugs/DB19215ApprovedFlorquinitau F 18 is a radioactive diagnostic drug used as a fluorine-18–labeled positron emission tomography (PET) tracer. … [L64052] It binds to aggregated tau protein, which in Alzheimer's disease forms the neurofibrillary tangles (NFTs) that are one of the two components required for a neuropathological diagnosis of the disease
Tipifarnib
go.drugbank.com/drugs/DB04960InvestigationalIn June 2005, the FDA issued a Not Approvable Letter for Zarnestra. … Tipifarnib (R-115777) is a substance that is being studied in the treatment of acute myeloid leukemia (AML) and other types of cancer.
Phosphorus P-32
go.drugbank.com/drugs/DB14551InvestigationalPhosphorus P-32 is a radioactive isotope of phosphorus with beta particle-emitting radiocytotoxic activity. … Emitted by phosphorus P32, beta particles directly damage cellular DNA and, by ionizing intracellular water to produce several types of cytotoxic free radicals and superoxides, indirectly damage intracellular
Stepronin
go.drugbank.com/drugs/DB01423ExperimentalStrepronin is a mucolytic drug. A mucolytic agent is any agent which dissolves thick mucus usually used to help relieve respiratory difficulties. … The viscosity of mucous secretions in the lungs is dependent upon the concentrations of mucoprotein as well as the presence of disulfide bonds between these macromolecules and DNA.